DE60032795D1 - Nordihydroguaiaretinsäurederivate zur behandlung von tumoren - Google Patents
Nordihydroguaiaretinsäurederivate zur behandlung von tumorenInfo
- Publication number
- DE60032795D1 DE60032795D1 DE60032795T DE60032795T DE60032795D1 DE 60032795 D1 DE60032795 D1 DE 60032795D1 DE 60032795 T DE60032795 T DE 60032795T DE 60032795 T DE60032795 T DE 60032795T DE 60032795 D1 DE60032795 D1 DE 60032795D1
- Authority
- DE
- Germany
- Prior art keywords
- tumors
- treatment
- acid derivatives
- nordihydroguaiaretinic acid
- nordihydroguaiaretinic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US418594 | 1999-10-15 | ||
US09/418,594 US6214874B1 (en) | 1999-10-15 | 1999-10-15 | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
PCT/US2000/028612 WO2001028494A2 (en) | 1999-10-15 | 2000-10-16 | Nordihydroguaiaretic derivatives for use in treatment of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60032795D1 true DE60032795D1 (de) | 2007-02-15 |
DE60032795T2 DE60032795T2 (de) | 2007-11-08 |
Family
ID=23658774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60032795T Expired - Lifetime DE60032795T2 (de) | 1999-10-15 | 2000-10-16 | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren |
Country Status (11)
Country | Link |
---|---|
US (4) | US6214874B1 (de) |
EP (1) | EP1231914B1 (de) |
JP (2) | JP4062664B2 (de) |
CN (1) | CN1309381C (de) |
AT (1) | ATE350030T1 (de) |
AU (1) | AU783015C (de) |
CA (1) | CA2387873C (de) |
DE (1) | DE60032795T2 (de) |
HK (1) | HK1050860A1 (de) |
SG (1) | SG144712A1 (de) |
WO (1) | WO2001028494A2 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
US20060073530A1 (en) * | 2001-08-15 | 2006-04-06 | Olaf Schneewind | Methods and compositions involving sortase B |
AU2004249124A1 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
US7728036B2 (en) * | 2003-05-20 | 2010-06-01 | Erimos Pharmaceuticals, Llc | Methods for delivery of catecholic butanes for treatment of tumors |
CN100440843C (zh) * | 2004-05-12 | 2008-12-03 | 华为技术有限公司 | 一种环网及其业务实现方法 |
WO2005117849A1 (en) | 2004-05-28 | 2005-12-15 | Unigen Pharmaceuticals, Inc. | Diarylalkanes as potent inhibitors of binuclear enzymes |
WO2006014669A2 (en) * | 2004-07-20 | 2006-02-09 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
US8440648B2 (en) * | 2004-07-20 | 2013-05-14 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
US20080207532A1 (en) * | 2004-10-06 | 2008-08-28 | Johns Hopkins University | Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection |
ES2606332T3 (es) * | 2005-01-27 | 2017-03-23 | Erimos Pharmaceuticals Llc | Formulaciones orales para la administración de butanos catecólicos incluyendo compuestos de NDGA |
US20090155349A1 (en) * | 2006-02-23 | 2009-06-18 | Jonathan Daniel Heller | Methods of treating influenza viral infections |
WO2008042896A2 (en) * | 2006-10-02 | 2008-04-10 | Erimos Pharmaceuticals Llc | Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
US9067875B2 (en) | 2006-10-02 | 2015-06-30 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
WO2008088806A1 (en) * | 2007-01-16 | 2008-07-24 | Johns Hopkins University | Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants |
PL2150218T3 (pl) * | 2007-05-11 | 2016-12-30 | Urządzenie stomijne | |
KR102527742B1 (ko) * | 2008-07-21 | 2023-04-28 | 유니젠, 인크. | 일련의 피부-화이트닝(라이트닝) 화합물 |
WO2010011117A2 (ko) * | 2008-07-25 | 2010-01-28 | 국립암센터 | Ndga를 포함하는 트란스글루타미나제 억제용 조성물 |
US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
EP2349235A1 (de) * | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Verwendung von catecholbutan-derivaten in der krebstherapie |
CA2830993C (en) | 2011-03-24 | 2019-07-02 | Unigen, Inc. | Compounds and methods for preparation of diarylpropanes |
US9084779B2 (en) | 2011-05-31 | 2015-07-21 | The Johns Hopkins University | Conjugates of nitroimidazoles and their use as chemotherapeutic agents |
US9456995B2 (en) | 2012-07-18 | 2016-10-04 | The Johns Hopkins University | Methods for inhibition of BNIP3 and prevention and treatment of ischemia reperfusion injury by tetra-O-methyl nordihydroguaiaretic acid |
AU2014223548A1 (en) | 2013-02-26 | 2015-10-15 | Triact Therapeutics, Inc. | Cancer therapy |
EP3044593A4 (de) * | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Krebstherapie |
MX2017002227A (es) | 2017-02-17 | 2018-08-16 | Promotora Tecnica Ind S A De C V | Composicion mejorada a base de acido norhidroguayaretico. |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
US5276060A (en) * | 1979-06-19 | 1994-01-04 | Block/Chemex, G.P. | Methods of treating tumors with compositions of catecholic butanes |
DE3009542A1 (de) * | 1980-03-13 | 1981-09-24 | Henkel KGaA, 4000 Düsseldorf | Desodorierende kosmetische zusammensetzungen |
US4774229A (en) * | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
US4880637A (en) * | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
US5559149A (en) * | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
US5646186A (en) * | 1994-05-17 | 1997-07-08 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
US6071949A (en) * | 1995-03-14 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
US5837252A (en) | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
-
1999
- 1999-10-15 US US09/418,594 patent/US6214874B1/en not_active Expired - Lifetime
-
2000
- 2000-10-16 AU AU12075/01A patent/AU783015C/en not_active Ceased
- 2000-10-16 WO PCT/US2000/028612 patent/WO2001028494A2/en active IP Right Grant
- 2000-10-16 US US09/690,063 patent/US6417234B1/en not_active Expired - Lifetime
- 2000-10-16 CN CNB008160228A patent/CN1309381C/zh not_active Expired - Lifetime
- 2000-10-16 DE DE60032795T patent/DE60032795T2/de not_active Expired - Lifetime
- 2000-10-16 JP JP2001531090A patent/JP4062664B2/ja not_active Expired - Lifetime
- 2000-10-16 EP EP00973576A patent/EP1231914B1/de not_active Expired - Lifetime
- 2000-10-16 CA CA002387873A patent/CA2387873C/en not_active Expired - Lifetime
- 2000-10-16 SG SG200402053-3A patent/SG144712A1/en unknown
- 2000-10-16 AT AT00973576T patent/ATE350030T1/de not_active IP Right Cessation
-
2002
- 2002-04-11 US US10/119,899 patent/US6958411B2/en not_active Expired - Lifetime
-
2003
- 2003-05-06 HK HK03103192A patent/HK1050860A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 US US11/121,093 patent/US20050267208A1/en not_active Abandoned
-
2007
- 2007-10-09 JP JP2007263845A patent/JP2008019278A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP4062664B2 (ja) | 2008-03-19 |
ATE350030T1 (de) | 2007-01-15 |
CN1391471A (zh) | 2003-01-15 |
DE60032795T2 (de) | 2007-11-08 |
EP1231914A2 (de) | 2002-08-21 |
WO2001028494A3 (en) | 2002-01-10 |
US6214874B1 (en) | 2001-04-10 |
CA2387873A1 (en) | 2001-04-26 |
SG144712A1 (en) | 2008-08-28 |
US6417234B1 (en) | 2002-07-09 |
US20050267208A1 (en) | 2005-12-01 |
EP1231914A4 (de) | 2004-04-14 |
JP2008019278A (ja) | 2008-01-31 |
AU783015B2 (en) | 2005-09-15 |
WO2001028494A2 (en) | 2001-04-26 |
CN1309381C (zh) | 2007-04-11 |
CA2387873C (en) | 2008-12-30 |
EP1231914B1 (de) | 2007-01-03 |
US20030065016A1 (en) | 2003-04-03 |
AU783015C (en) | 2006-08-24 |
WO2001028494A9 (en) | 2002-08-01 |
HK1050860A1 (en) | 2003-07-11 |
US6958411B2 (en) | 2005-10-25 |
AU1207501A (en) | 2001-04-30 |
JP2003511477A (ja) | 2003-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
ATE308997T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60023043D1 (de) | (S,S)-Reboxetin zur Behandlung von Inkontinenz | |
DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE455106T1 (de) | Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen | |
DE60023982D1 (de) | System zur Behandlung von benigner Prostatahyperplasie | |
ATE400283T1 (de) | Reovirus zur behandlung von zellulären proliferativen erkrankungen | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE60030554T8 (de) | Verwendungen von et743 zur behandlung von krebs | |
DE60031790D1 (de) | Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen | |
ATE233483T1 (de) | Wässrige lösung zum konservieren von gewebe und organen | |
ATE347372T1 (de) | Vakzine zur behandlung von mycosen | |
ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
DE60018200D1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
ATE299371T1 (de) | Antikonvulsiva zur behandlung von autismus | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
ATE261724T1 (de) | Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: HUANG, RU CHIH C, BALTIMORE, MD., US Inventor name: HELLER, JONATHAN, DUNDALK, MD., US Inventor name: HWU, JIH RU, HSINCHU, TW Inventor name: KING, KE YUNG, HSINCHU, TW Inventor name: HAKIMELAHI, GHOLAM HOSEIN, NANKANG, TAIPEI, TW |
|
8364 | No opposition during term of opposition |